Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Raw Materials (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Raw Materials for 4 consecutive years, with $10.4 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 8.76% to $10.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Dec 2025, up 8.76% year-over-year, with the annual reading at $10.4 million for FY2025, 8.76% up from the prior year.
  • Raw Materials hit $10.4 million in Q4 2025 for Axsome Therapeutics, down from $12.4 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $12.4 million in Q3 2025 to a low of $2.1 million in Q3 2022.
  • Historically, Raw Materials has averaged $7.1 million across 4 years, with a median of $6.7 million in 2024.
  • Biggest five-year swings in Raw Materials: surged 123.78% in 2023 and later increased 8.76% in 2025.
  • Year by year, Raw Materials stood at $2.5 million in 2022, then surged by 123.78% to $5.5 million in 2023, then soared by 72.41% to $9.5 million in 2024, then rose by 8.76% to $10.4 million in 2025.
  • Business Quant data shows Raw Materials for AXSM at $10.4 million in Q4 2025, $12.4 million in Q3 2025, and $11.7 million in Q2 2025.